Literature DB >> 11311047

Mechanism of asparagine deamidation during human senile cataractogenesis.

L Takemoto1, N Fujii, D Boyle.   

Abstract

Previous studies have demonstrated that asparagine-143 of gammaS crystallin is preferentially deamidated in human cataractous lenses. A possible mechanism of nonenzymatic deamidation involves the initial formation of L -succinimidyl and D -succinimidyl intermediates, followed by ring cleavage and production of the respective L - and D - forms of beta-aspartate and alpha-aspartate. To determine if this mechanism occurs during cataractogenesis of the human lens, synthetic peptide standards together with reverse phase HPLC were used to purify and quantitate tryptic peptides from cataractous lenses that contained the beta-aspartate and alpha-aspartate forms of residue 143. For all lenses analysed, the ratios of beta-aspartate/alpha-aspartate produced were consistent with a mechanism of deamidation involving succinimide intermediates. Surprisingly, the D / L ratios for all beta- and alpha-aspartates produced were very low, suggesting that the mechanism of deamidation preferentially involves the L -succinimidyl intermediate, with formation of the D -succinimidyl intermediate almost completely blocked by steric hindrance. Together, the results demonstrate that deamidation of asparagine-143 from gammaS crystallin of different human cataracts undergoes the same mechanism, which due to higher ordered structure of the native protein, results in the preferential production of one of two possible succinimidyl intermediates. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311047     DOI: 10.1006/exer.2001.0983

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  9 in total

Review 1.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 2.  Biophysical chemistry of the ageing eye lens.

Authors:  Nicholas J Ray
Journal:  Biophys Rev       Date:  2015-08-23

Review 3.  Lens β-crystallins: the role of deamidation and related modifications in aging and cataract.

Authors:  Kirsten J Lampi; Phillip A Wilmarth; Matthew R Murray; Larry L David
Journal:  Prog Biophys Mol Biol       Date:  2014-03-06       Impact factor: 3.667

4.  A novel assay method for an amino acid racemase reaction based on circular dichroism.

Authors:  Masafumi Noda; Yasuyuki Matoba; Takanori Kumagai; Masanori Sugiyama
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

5.  Deamidation of Human γS-Crystallin Increases Attractive Protein Interactions: Implications for Cataract.

Authors:  Ajay Pande; Natalya Mokhor; Jayanti Pande
Journal:  Biochemistry       Date:  2015-07-29       Impact factor: 3.162

6.  Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody.

Authors:  Sandipan Sinha; Lei Zhang; Shaofeng Duan; Todd D Williams; Josef Vlasak; Roxana Ionescu; Elizabeth M Topp
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

7.  The impact of extra-domain structures and post-translational modifications in the folding/misfolding behaviour of the third PDZ domain of MAGUK neuronal protein PSD-95.

Authors:  Javier Murciano-Calles; Marta Marin-Argany; Eva S Cobos; Sandra Villegas; Jose C Martinez
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

8.  Post-translational modifications modulate ligand recognition by the third PDZ domain of the MAGUK protein PSD-95.

Authors:  Javier Murciano-Calles; Carles Corbi-Verge; Adela M Candel; Irene Luque; Jose C Martinez
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

9.  Interaction of βA3-Crystallin with Deamidated Mutants of αA- and αB-Crystallins.

Authors:  Ekta Tiwary; Shylaja Hegde; Sangeetha Purushotham; Champion Deivanayagam; Om Srivastava
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.